Equillium, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EQ research report →
About the company
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor.
- CEO
- Bruce D. Steel
- IPO
- 2018
- Employees
- 35
- HQ
- La Jolla, CA, US
Price Chart
- Market Cap
- $103.37M
- P/E
- -7.73
- P/S
- 0.00
- P/B
- 4.71
- EV/EBITDA
- -2.26
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -61.43%
- ROIC
- -33.86%
- Revenue
- $0 · -100.00%
- Net Income
- $-22,398,000 · -177.65%
- EPS
- $-0.39 · -69.57%
- Op Income
- $-23,634,000
- FCF YoY
- -19.27%
- 52W High
- $3.54
- 52W Low
- $0.29
- 50D MA
- $2.54
- 200D MA
- $1.75
- Beta
- 1.78
- Avg Volume
- 716.42K
Get TickerSpark's AI analysis on EQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 5, 26 | Zedelmayer Christine | other | 14,584 |
| Jun 5, 26 | Zedelmayer Christine | sell | 14,584 |
| Jun 5, 26 | Zedelmayer Christine | other | 14,584 |
| Jun 4, 26 | Connelly Stephen | sell | 200,000 |
| Jun 5, 26 | Connelly Stephen | sell | 30,975 |
| May 28, 26 | Tom Penny | other | 65,000 |
| May 28, 26 | Tom Penny | sell | 65,000 |
| May 28, 26 | Tom Penny | other | 65,000 |
| May 28, 26 | DEMSKI MARTHA J | other | 70,000 |
| May 28, 26 | Pruzanski Mark | other | 70,000 |
Our EQ coverage
Recent articles, reports, and earnings notes.
No research on EQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EQ report →Similar companies
Peers in the same neighborhood.